|
Download
PDF
|
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs
Introduction
Only 15-20% of pancreatic cancer patients have resectable
disease, therefore most receive systemic therapy. Gemzar (gemcitabine;
Eli Lilly) forms the current standard of care for advanced
disease. Despite this, no treatment is truly effective, with
five-year survival at 5% for all stages of disease. Significant
unmet needs therefore remain, with ample commercial
opportunities for drug developers.
Scope
-
Pancreatic cancer overview,
including definition, risk factors, epidemiology forecasts and
discussion of unmet needs
-
Current diagnosis and treatment
of pancreatic cancer, including drug regimens used by stage and
ongoing controversies
-
Examination of the late-phase
pancreatic cancer pipeline and market opportunities for drug
developers
-
Stakeholder opinions based on
qualitative interviews with key opinion leaders in the field of
pancreatic cancer
Highlights
Gemzar is the current
standard of care for unresectable locally advanced and
metastatic pancreatic cancer. Despite this, Gemzar is only
associated with median overall survival of 5.7 months and a
one-year survival rate of 18%. It is therefore clear that
treatment of pancreatic cancer continues to be plagued by high
levels of unmet need.
Other lines of therapy in pancreatic cancer remain ill defined
due to a lack of definitive randomized clinical trial data.
Controversy persists regarding the use of neoadjuvant versus
adjuvant therapy, while the role of radiotherapy alongside
chemotherapy in these settings continues to provoke debate.
The pancreatic cancer pipeline is relatively active, with six
Phase III agents. Despite this, Gemzar is set to retain its
leading status for the foreseeable future. While promising Phase
II results have been shown, this has yet to be translated into
Phase III efficacy. As a result, no pipeline agent has yet shown
the potential to replace Gemzar.
Reasons to Purchase
-
Identify the limitations of
current therapy available to pancreatic cancer patients and the
potential of future therapy
-
Understand current
epidemiological trends in pancreatic cancer and ongoing
treatment controversies
-
Assess the opportunities for
innovative targeted therapies in the pancreatic cancer market,
particularly in metastatic disease
View
Table Of Contents >
|
